241 related articles for article (PubMed ID: 16891395)
1. Analysis of methylarginine metabolism in the cardiovascular system identifies the lung as a major source of ADMA.
Bulau P; Zakrzewicz D; Kitowska K; Leiper J; Gunther A; Grimminger F; Eickelberg O
Am J Physiol Lung Cell Mol Physiol; 2007 Jan; 292(1):L18-24. PubMed ID: 16891395
[TBL] [Abstract][Full Text] [Related]
2. Increased symmetrical dimethylarginine in ischemic acute kidney injury as a causative factor of renal L-arginine deficiency.
Betz B; Möller-Ehrlich K; Kress T; Kniepert J; Schwedhelm E; Böger RH; Wanner C; Sauvant C; Schneider R
Transl Res; 2013 Aug; 162(2):67-76. PubMed ID: 23707198
[TBL] [Abstract][Full Text] [Related]
3. Age-related changes in ADMA-DDAH-NO pathway in rat liver subjected to partial ischemia followed by global reperfusion.
Trocha M; Merwid-Ląd A; Chlebda-Sieragowska E; Szuba A; Pieśniewska M; Fereniec-Gołębiewska L; Kwiatkowska J; Szeląg A; Sozański T
Exp Gerontol; 2014 Feb; 50():45-51. PubMed ID: 24269305
[TBL] [Abstract][Full Text] [Related]
4. From arginine methylation to ADMA: a novel mechanism with therapeutic potential in chronic lung diseases.
Zakrzewicz D; Eickelberg O
BMC Pulm Med; 2009 Jan; 9():5. PubMed ID: 19178698
[TBL] [Abstract][Full Text] [Related]
5. Asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA) and homoarginine (hArg): the ADMA, SDMA and hArg paradoxes.
Tsikas D; Bollenbach A; Hanff E; Kayacelebi AA
Cardiovasc Diabetol; 2018 Jan; 17(1):1. PubMed ID: 29301528
[TBL] [Abstract][Full Text] [Related]
6. Dimethylarginine dimethylaminohydrolase-1 is the critical enzyme for degrading the cardiovascular risk factor asymmetrical dimethylarginine.
Hu X; Atzler D; Xu X; Zhang P; Guo H; Lu Z; Fassett J; Schwedhelm E; Böger RH; Bache RJ; Chen Y
Arterioscler Thromb Vasc Biol; 2011 Jul; 31(7):1540-6. PubMed ID: 21493890
[TBL] [Abstract][Full Text] [Related]
7. Reduced Renal Methylarginine Metabolism Protects against Progressive Kidney Damage.
Tomlinson JA; Caplin B; Boruc O; Bruce-Cobbold C; Cutillas P; Dormann D; Faull P; Grossman RC; Khadayate S; Mas VR; Nitsch DD; Wang Z; Norman JT; Wilcox CS; Wheeler DC; Leiper J
J Am Soc Nephrol; 2015 Dec; 26(12):3045-59. PubMed ID: 25855779
[TBL] [Abstract][Full Text] [Related]
8. [Biological and pathophysiological roles of endogenous methylarginines as inhibitors of nitric oxide synthase].
Masuda H; Azuma H
Nihon Yakurigaku Zasshi; 2002 Jan; 119(1):29-35. PubMed ID: 11862754
[TBL] [Abstract][Full Text] [Related]
9. Colocalization of demethylating enzymes and NOS and functional effects of methylarginines in rat kidney.
Tojo A; Welch WJ; Bremer V; Kimoto M; Kimura K; Omata M; Ogawa T; Vallance P; Wilcox CS
Kidney Int; 1997 Dec; 52(6):1593-601. PubMed ID: 9407505
[TBL] [Abstract][Full Text] [Related]
10. Resolution and quantification of arginine, monomethylarginine, asymmetric dimethylarginine, and symmetric dimethylarginine in plasma using HPLC with internal calibration.
Alkaitis MS; Nardone G; Chertow JH; Ackerman HC
Biomed Chromatogr; 2016 Mar; 30(3):294-300. PubMed ID: 26130049
[TBL] [Abstract][Full Text] [Related]
11. Ammonia Reduces Intracellular Asymmetric Dimethylarginine in Cultured Astrocytes Stimulating Its y⁺LAT2 Carrier-Mediated Loss.
Milewski K; Bogacińska-Karaś M; Fręśko I; Hilgier W; Jaźwiec R; Albrecht J; Zielińska M
Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29099056
[TBL] [Abstract][Full Text] [Related]
12. Molecular mechanism for elevation of asymmetric dimethylarginine and its role for hypertension in chronic kidney disease.
Matsuguma K; Ueda S; Yamagishi S; Matsumoto Y; Kaneyuki U; Shibata R; Fujimura T; Matsuoka H; Kimoto M; Kato S; Imaizumi T; Okuda S
J Am Soc Nephrol; 2006 Aug; 17(8):2176-83. PubMed ID: 16807406
[TBL] [Abstract][Full Text] [Related]
13. Asymmetric dimethylarginine (ADMA) as a target for pharmacotherapy.
Bełtowski J; Kedra A
Pharmacol Rep; 2006; 58(2):159-78. PubMed ID: 16702618
[TBL] [Abstract][Full Text] [Related]
14. Asymmetric dimethylarginine, an endogenous NOS inhibitor, is actively metabolized in rat erythrocytes.
Yokoro M; Suzuki M; Murota K; Otsuka C; Yamashita H; Takahashi Y; Tsuji H; Kimoto M
Biosci Biotechnol Biochem; 2012; 76(7):1334-42. PubMed ID: 22785485
[TBL] [Abstract][Full Text] [Related]
15. Asymmetric dimethylarginine (ADMA) as an important risk factor for the increased cardiovascular diseases and heart failure in chronic kidney disease.
Liu X; Xu X; Shang R; Chen Y
Nitric Oxide; 2018 Aug; 78():113-120. PubMed ID: 29928990
[TBL] [Abstract][Full Text] [Related]
16. Biological significance of endogenous methylarginines that inhibit nitric oxide synthases.
Leiper J; Vallance P
Cardiovasc Res; 1999 Aug; 43(3):542-8. PubMed ID: 10690326
[TBL] [Abstract][Full Text] [Related]
17. Disruption of methylarginine metabolism impairs vascular homeostasis.
Leiper J; Nandi M; Torondel B; Murray-Rust J; Malaki M; O'Hara B; Rossiter S; Anthony S; Madhani M; Selwood D; Smith C; Wojciak-Stothard B; Rudiger A; Stidwill R; McDonald NQ; Vallance P
Nat Med; 2007 Feb; 13(2):198-203. PubMed ID: 17273169
[TBL] [Abstract][Full Text] [Related]
18. Asymmetric dimethylarginine, derangements of the endothelial nitric oxide synthase pathway, and cardiovascular diseases.
Böger RH; Bode-Böger SM
Semin Thromb Hemost; 2000; 26(5):539-45. PubMed ID: 11129410
[TBL] [Abstract][Full Text] [Related]
19. Plasma concentrations of arginine and asymmetric dimethylarginine do not reflect their intracellular concentrations in peripheral blood mononuclear cells.
Davids M; Teerlink T
Metabolism; 2013 Oct; 62(10):1455-61. PubMed ID: 23890667
[TBL] [Abstract][Full Text] [Related]
20. AGXT2 and DDAH-1 genetic variants are highly correlated with serum ADMA and SDMA levels and with incidence of coronary artery disease in Egyptians.
Amir M; Hassanein SI; Abdel Rahman MF; Gad MZ
Mol Biol Rep; 2018 Dec; 45(6):2411-2419. PubMed ID: 30284143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
